This inventor holds 1 USPTO granted patent. Top assignee: Kanebo, Limited. Active years: 1999.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 1999
Title: An Insight into Inventor Masayuki Ando
Introduction
Masayuki Ando, a notable inventor based in Osaka-fu, Japan, has made significant contributions to the field of pharmaceuticals. With a focus on anti-tumor agents, his innovative work has been recognized within the scientific community.
Latest Patents
Ando holds a patent for a quinazoline compound, which is crucial in the development of anti-tumor agents. The patent describes a quinazoline compound represented by a specific formula, which serves as an active ingredient in pharmaceutical compositions aimed at combatting tumors. This innovation reflects the ongoing efforts to enhance cancer treatment methods through chemical compounds.
Career Highlights
Working at Kanebo, Limited, Masayuki Ando has leveraged his expertise to advance pharmaceutical developments. His career is marked by a dedication to improving therapeutic solutions, particularly in oncology, showcasing the intersection of chemistry and medicine.
Collaborations
Throughout his career, Ando has collaborated with distinguished colleagues such as Yoshikazu Jinbo and Tomohiro Miyasaka. These partnerships have fostered a collaborative environment that drives innovation and enhances research quality, contributing to the success of the projects they undertake.
Conclusion
Masayuki Ando's contributions to the field of pharmaceuticals, particularly through his patent on a quinazoline compound, underscore his role as an influential inventor. His ongoing work at Kanebo, Limited, and collaborations with skilled professionals highlight the importance of teamwork in advancing scientific discoveries. As the fight against cancer continues, the innovations developed by Ando and his colleagues are essential in paving the way for more effective treatments.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
